

Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Alissa J. Cooper, Lecia V. Sequist  and Jessica J. Lin 

Correction to: *Nature Reviews Clinical Oncology* <https://doi.org/10.1038/s41571-022-00639-9>, published online 9 May 2022.

In the version of this article initially published, the first paragraph of the “Consideration of immunotherapy” section contained incorrect hazard ratios and associated confidence intervals. “HR 1.0, 95% CI 0.57–1.74” for all patients with *EGFR*-mutant NSCLC has been corrected to “HR 0.60, 95% CI 0.31–1.14.” Similarly, “HR 1.22, 95% CI 0.68–2.22” for patients who had received a previous TKI has been corrected to “HR 0.74, 95% CI 0.38–1.46.” The changes have been made to the HTML and PDF versions of the article.

<https://doi.org/10.1038/s41571-022-00680-8> | Published online 15 August 2022

© Springer Nature Limited 2022